久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國BioVascular Inc
BioVascular公司是一家私人持股公司，開發生物技術藥物和設備的控制內膜增生與血管有關的程序和控制的危險因素與心血管發病率和死亡率。BioVascular的主導產品， saratin ，是一種多肽生產中酵母重組手段。該產品是授權默克制藥公司于2005年。 BioVascular開始人體臨床試驗的saratin血液透析移植準入和在2006年年底將開始人體試驗治療周圍動脈移植在2007年年初。

BioVascular的第二個產品利用了一種新型機制，減少了最近界定心血管危險因素。該產品將進入人體試驗階段在2007年年中。
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.

BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.

BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.